Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 23, 2026

Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes
06:09

Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes

Published on: June 22, 2016

Generating tolerogenic dendritic cells with neuropeptides.

Mario Delgado1

  • 1Instituto de Parasitologia y Biomedicina, Consejo Superior de Investigaciones Cientificas, Granada 18100, Spain. mdelgado@ipb.csic.es

Human Immunology
|May 1, 2009
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cortistatin as a Novel Multimodal Therapy for the Treatment of Parkinson's Disease.

International journal of molecular sciences·2024
Same author

A potential patient stratification biomarker for Parkinson´s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells.

NPJ Parkinson's disease·2024
Same author

Novel Therapeutic Opportunities for Neurodegenerative Diseases with Mesenchymal Stem Cells: The Focus on Modulating the Blood-Brain Barrier.

International journal of molecular sciences·2023
Same author

Therapeutic Effect of a Latent Form of Cortistatin in Experimental Inflammatory and Fibrotic Disorders.

Pharmaceutics·2022
Same author

Editorial: The innate immune system in rheumatoid arthritis.

Frontiers in immunology·2022
Same author

Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis.

Pharmaceutics·2022
Same journal

The significance of galectin-9 and T-cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) in patients with chronic lymphocytic leukemia: The role of immune evasion.

Human immunology·2026
Same journal

The functional relevance of human leukocyte antigens in the development of cord blood derived advanced cellular therapies: A new direction of public cord blood banks.

Human immunology·2026
Same journal

From educational to graded: redefining proficiency testing in ABO genotyping.

Human immunology·2026
Same journal

Recurrent spontaneous abortion: integrated bioinformatics and histological validation identify FURIN and NEDD4 as ferroptosis-associated endometrial markers.

Human immunology·2026
Same journal

A perspective on ABO incompatible transplantation.

Human immunology·2026
Same journal

Classical HLA allele and haplotype frequency estimates in US populations.

Human immunology·2026
See all related articles

Neuropeptides like VIP and PACAP can induce tolerogenic dendritic cells (DCs) to promote immune tolerance. This finding offers potential new therapies for autoimmune diseases and transplant rejection.

Area of Science:

  • Immunology
  • Neuroendocrinology
  • Cell Biology

Background:

  • Antigen-specific tolerance is crucial for preventing autoimmunity and maintaining immune homeostasis.
  • Dendritic cells (DCs) are key regulators of peripheral tolerance, influencing regulatory T (Treg) cell populations.
  • Neuropeptides, produced during inflammation, act as endogenous anti-inflammatory agents influencing self-tolerance.

Purpose of the Study:

  • To investigate the role of neuropeptides in modulating dendritic cell (DC) function and inducing immune tolerance.
  • To explore the therapeutic potential of neuropeptide-induced tolerogenic DCs for autoimmune diseases and transplantation.

Main Methods:

  • Review of current research on neuropeptide effects on dendritic cell differentiation and activation states.

More Related Videos

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

Related Experiment Videos

Last Updated: Jun 23, 2026

Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes
06:09

Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes

Published on: June 22, 2016

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

  • Analysis of neuropeptide-induced changes in DC function related to Treg cell induction.

    • Main Results:

    • Neuropeptides differentially affect DC functions based on their differentiation and activation states.
    • Vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), and melanocyte-stimulating hormone (MSH) induce tolerogenic DCs.
    • These DCs can generate both CD4+ and CD8+ Treg cells.

    Conclusions:

    • Neuropeptides play a significant role in immune tolerance, partly through their influence on DCs.
    • Ex vivo generation or expansion of tolerogenic DCs using neuropeptides shows therapeutic promise for autoimmune conditions and graft-versus-host disease.